Evaluating disparities in precision oncology for metastatic cancer patients
Evaluating Disparities in Precision Oncology: An Observational Trial in the Context of a Real-World Academic Practice Model
This study looks at how different social factors affect the treatment and outcomes for people with metastatic cancer to help understand why some patients do better than others.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Indiana University Academic / other |
| Locations | 1 site (Indianapolis, Indiana) |
| Trial ID | NCT06081517 on ClinicalTrials.gov |
What this trial studies
This observational trial aims to collect comprehensive clinical, social, and genomic data from patients with metastatic cancer enrolled in molecular oncology tumor boards at four comprehensive cancer centers. By leveraging real-world data, the study seeks to identify factors contributing to disparities in survival and toxicity outcomes among diverse patient populations. The approach focuses on understanding how social determinants of health impact treatment efficacy and patient experiences in precision medicine.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are planning to undergo molecular testing as part of their routine cancer care.
Not a fit: Patients who are not undergoing molecular testing or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and mitigation of disparities in treatment outcomes for metastatic cancer patients.
How similar studies have performed: While there have been studies focusing on precision medicine, this specific approach to evaluating disparities in outcomes using real-world data is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ability to provide written informed consent and HIPAA authorization 2. Patients must be ≥ 18 years old at the time of consent 3. Patients planning to undergo molecular testing as part of their routine cancer care Exclusion Criteria: N/A
Where this trial is running
Indianapolis, Indiana
- Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States (Recruiting)
Study contacts
- Principal investigator: Bryan P Schneider, MD — Indiana University
- Study coordinator: Maria McQuade, BA
- Email: mcquadem@iu.edu
- Phone: (317) 278-5238
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.